How humanity's second-largest "killer" depression can be treated How stem cells can help patients

Depression is a mental disorder caused by a variety of causes, mainly depression.
clinically, chronic progression, recurrent seizures, mainly show patients depressed mood, loss of interest or enjoyment, guilt, or low self-esteem, sleep and appetite disorders and other symptoms.
At present, due to the fierce competition in society, the accelerated pace of work and life, as well as the mental stress of chronic diseases, the prevalence of depression, recurrence rate, suicide rate and disease burden are high, has become one of the major problems in public health.
depression is the world's second largest source of disease 2019 survey data show that China's lifetime prevalence of depressive disorders reached 6.8%, about 95 million patients, becoming the second largest source of disease burden after cardiovascular disease.
, adolescent depression is more than 50 percent and high school students are 40 percent.
, depression has attracted great attention from the state.
September 11, 2020, the General Office of the National Health And Wellness Commission issued the Work Programme on Exploring Special Services for the Prevention and Control of Depression.
effective treatment of depression is an urgent problem to be solved now and in the future, and the treatment of depression will be a great challenge.
clinical studies have found an increase in gene transcriptional expression levels of inflammatory factors such as lecytokine 1 beta, lebinocyte mesokine 6 and tumor necrotic cause α in patients with depression.
factors such as pro-inflammatory factors, monoamine neurotransmitter and hypothyroidism-pituitary gland-adrenal axis, neurotrophic factor disorder and sea horse neuron injury and remodeling are involved in the occurrence and development of depression.
stem cells have the potential of multi-way differentiation, can be differentiated into neural stem cells, participate in anti-inflammatory and tissue repair, is widely used in stroke, neurodegenerative diseases and spinal cord injury and other neurological diseases treatment.
stem cells on the path to depression treatment As of November 2020, 35 clinical research projects on stem cells for depression have been registered on the National Institutes of Health's largest clinical trial registry website.
2019, the scientific research team of the Scientific Research Experimental Center of the Basic Medical College of Henan University of Traditional Chinese Medicine treated patients with post-stroke depression with the combined interstumic stem cells of kata dangun.
study, 60 patients with post-stroke depression were randomly divided into observational and control groups of 30.
the course of the study, the observation group was given the treatment of the combined charge stem cells of the flavored dander, and the control group was given the treatment of the combined fluoroxitine of the caramed dander, both of which were treated for 8 weeks.
two groups of patients were assessed using the Hamilton Depression Scale (HAMD) before and after treatment.
8 weeks of treatment, the total efficiency of the observation group was significantly higher than that of the control group.
Therefore, it is believed that the effect of the treatment of post-stroke depression with the combined interstitial-charged stem cells of flavored dander is better, and its mechanism may be related to the anti-inflammatory stem cells, increase the release of monoamine-type neurotransmitters, and stimulate the secretion of neurotrophic factors in the brain.
In addition, researchers at the University of Miami in Florida conducted a study in March 2018 on the treatment of patients with alcohol use disorders and severe depression in a placebo-controlled study to assess the potential efficacy of allogeneic human-filled stem cell infusions and placebos for patients with alcohol use disorders and severe depression, according to the National Institutes of Health's largest clinical trial registry website.
the study randomly included 80 volunteers and conducted interventional therapy (clinical trials).
the experimental group will receive a treatment of allogeneic interstate-filled stem cells at a dose of 1× 10 to 8 (100 million) and intravenous infusions during the week.
control group were given a placebo consisting of 1% of the serum protein in a single exofon.
clinical improvement was rated on a 7-point scale, with assessments from 1 (ideal) to 7 (very poor), and the project is expected to be completed by April 2025.
although there are not many current clinical studies on the treatment of depression with interstume stem cells, the results of these published studies show that mesochargic stem cells have great prospects for improving depression.
more clinical trial results are also highly anticipated.
prospective interstititional stem cells belong to a kind of multi-functional stem cells, in addition to high self-renewal ability, multi-way differentiation potential, low immunogenicity, but also has a wide range of immune regulation.
clinical and basic studies have shown that interstitiotic stem cells can be a potentially effective treatment for a variety of incoming neuroimmune diseases, including depression, by regulating immunity.
of neuropathy is becoming more and more serious, and stem cell therapy technology will protect human mental health through basic research and clinical application research.
References: Chen Xiaohui, Wang Qiang, Shang Lizhi, et al. Clinical observation of the treatment of post-stroke depression by the combined umbilical cord-filled stem cells . . . Chinese Journal of Pathophysiology, 2019, 35 (12): 2274-2279.[2] [3] Tfilin M, Sudai E, Merenlender A, et al. Mesenchymal stem cells increase hippocampal neurogenesis and counteract depressive-like behavior[J]. Molecular Psychiatry, 2010,15(12): 1164-1175.[4] Park HJ, Oh SH, Kim HN, et al. Mesenchymal stem cells enhance alpha-synucleir clearance via M2 microglia polarization in experimental and human parkinsoniar disorder [J]. Acta Neuropathol, 2016. 132(5): 685-701.